[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 465
Citations 0
Comment & Response
March 12, 2014

Stem Cells and Cardiovascular Drug Development—Reply

Author Affiliations
  • 1Stanford University School of Medicine, Stanford, California
JAMA. 2014;311(10):1070-1071. doi:10.1001/jama.2014.634

In Reply Drs Rao and Dlouhy mention several valid points regarding the bottlenecks of iPSC derivation and suggest that direct reprogramming to induced cardiomyocytes (iCMs) may be a more cost-effective, efficient, and safe alternative. Transdifferentiation to iCMs presents both advantages and disadvantages compared with the use of iPSC-derived cardiomyocytes. We think that both of these methods offer significant potential for the clinical treatment of cardiac disease in addition to cardiovascular drug discovery.

First Page Preview View Large
First page PDF preview
First page PDF preview